During Tuesday’s Morning trade, Shares of Cempra Inc (NASDAQ:CEMP), lost -1.19% to $30.43.
Cempra, declared it has successfully accomplished enrollment of 250 patients in the United States and Australia for its Phase 3 trial in urogenital gonorrhea. Under a CRADA (Cooperative Research and Development Agreement) with the National Institute of Allergy and Infectious Diseases (NIAID), the Phase 3 trial has been amended to comprise up to an additional 60 patients, compriseing of women and adolescents with culture-proven gonorrhea.
“We have already accomplished patient enrollment of the first 250 patients, the majority of whom were men,” said Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra. “There is tremendous need for an effective, single dose, oral treatment such as solithromycin that can provide coverage for both gonococcus and chlamydia for the entire population at risk for these infections. We are happy that the NIAID will be expanding this study to enroll the additional patient populations that could eventually be comprised for the label indication, should solithromycin be approved for the treatment of urogenital gonorrhea. This potential use could be an attractive secondary market, in addition to the primary indication we are seeking for the treatment of community-attained bacterial pneumonia.”
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates comprise solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community attained bacterial pneumonia, in addition to for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has accomplished Phase II clinical trials for refractory bone and joint infections.
Shares of Tronox Ltd (NYSE:TROX), inclined 6.08% to $4.71, during its current trading session.
Park Lane Advisor has initiated coverage on the following equities: Tronox Ltd (TROX), Fairmount Santrol Holdings Inc. (FMSA), Rayonier Advanced Materials Inc. (RYAM), and Lake Shore Gold Corporation (NYSE MKT: LSG). Free research report on Tronox can be accessed at http://www.parklaneadvisor.com/ On Tuesday, December 22, 2015, the NASDAQ Composite ended at 5,001.11, up 0.65%, the Dow Jones Industrial Average advanced 0.96%, to finish the day at 17,417.27, and the S&P 500 closed at 2,038.97, up 0.88%. The gains were broad based as all the sectors ended the session in positive. Register for your complimentary reports at the links given below.
Tronox Ltd’s stock finished Tuesday’s session 14.65% higher at $4.07. A total of 1.49 million shares were traded, which was close to its three months average volume of 1.50 million shares. Over the last one month and the previous three months, Tronox Ltd’s shares have declined 11.90% and 24.91%, respectively. Additionally, the stock has plummeted 82.96% since the startning of 2015. The company’s shares are trading below their 50-day and 200-day moving averages by 26.95% and 66.51%, respectively. Tronox Ltd’s stock has a Relative Strength Index (RSI) of 43.99.
Tronox Limited produces and markets titanium bearing mineral sands and titanium dioxide (TiO2) pigment in North America, Europe, South Africa, and the Asia-Pacific region. It primarily operates in two segments, Mineral Sands and Pigment.
Finally, Verisk Analytics, Inc. (NASDAQ:VRSK), gained 0.51%, and is now trading at $77.56.
Catastrophe modeling firm AIR Worldwide, declared that its earthquake model for Peru has been officially approved by Peruvian insurance regulator Superintendencia de Banca y Seguros (SBS) to offer catastrophe modeling services to local insurance companies in the region. AIR Worldwide is a Verisk Analytics (VRSK) business.
Since 2005, Peruvian insurance companies have been required by the SBS 1305-2005 insurance resolution to contract with an SBS-approved catastrophe modeling company to have their catastrophe exposure quantified. With this new approval, local insurers can work directly with AIR Worldwide and obtain expert modeling services to satisfy regulatory requirements while giving companies a distinct advantage in preparing for the next great earthquake in the region.
Insurers in this region will be able to take advantage of AIR`s suite of earthquake models for South America, specifically Peru. The AIR Earthquake Models for South America are the first catastrophe models for the region to provide an integrated view of loss due to ground shaking, tsunami, and liquefaction. Taking into account the way earthquake potential builds up over time, the AIR models apply a novel “time-dependent” approach to account for the physics of recent earthquake ruptures and possible partial ruptures-yielding the most realistic view of seismic hazard available for Peru, Chile, Colombia, Ecuador, and Venezuela. In addition, the models feature new damage functions for high-value industrial facilities, builder`s risk, and public infrastructure to provide a comprehensive view of risk.
Verisk Analytics, Inc. provides information about risk to professionals in insurance, healthcare, financial services, government, supply chain, and risk administration in the United States and internationally. The company’s Risk Assessment segment offers solutions to P&C insurance customers and focuses on decision making processes in its risk analysis framework, counting prediction of loss, and selection and pricing of risk.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
